SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide, WIN 59075, tirapazamine) is the lead compound in a new class of bioreductive anticancer drugs, the benzotriazine di-N-oxides. It is currently undergoing Phase I clinical testing. The preferential tumour cell killing of SR 4233 is a result of its high specific toxicity to cells at low oxygen tensions. Such hypoxic cells are a common feature of solid tumours, but not normal tissues, and are resistant to cancer therapies including radiation and some anticancer drugs. The killing of these tumour cells by SR 4233, particularly when given on multiple occasions, can increase total tumour cell killing by fractionated irradiation by several orders of magnitude without increasing toxicity to surrounding normal tissues. Topics covered in this review include the rationale for developing a hypoxic cytotoxic agent, the cytotoxicity of SR 4233 as a function of oxygen concentration, the mechanism of action of the drug and its intracellular target and the in vivo evidence that the drug may be useful as an adjunct both to radiotherapy and chemotherapy. Finally, the major unanswered questions on the drug are outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaupel, P. W., Schlenger, K., Knoop, C., & Höckel, M. (1991) · PubMed · Cited by 1,118
Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., Hartz, W. H., & Broder, G. J. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(88)90002-8 · Cited by 798
Definitive evidence for hypoxic cells influencing cure in cancer therapy.
Bush, R. S., Jenkin, R. D. T., Allt, W. E. C., Beale, F. A., Bean, H. A., Dembo, A. J., & Pringle, J. F. (1978) · PubMed · Cited by 454
Bioactivation as a Model for Drug Design Bioreductive Alkylation
Moore, H. W. (1977) · Science · doi:10.1126/science.877572 · Cited by 430
Tumor hypoxia: its impact on cancer therapy
Moulder, J. E., & Rockwell, S. (1987) · Cancer and Metastasis Reviews · doi:10.1007/bf00055376 · Cited by 414
SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., & Lee, W. W. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90267-1 · Cited by 402
Self-citationCornforth, M. N., & Bedford, J. S. (1987) · Radiation Research · doi:10.2307/3576926 · Cited by 332
RADIOTHERAPY AND HYPERBARIC OXYGEN IN HEAD AND NECK CANCER
Henk, J. M., & Smith, C. W. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90117-9 · Cited by 320
Therapeutic attack of hypoxic cells of solid tumors: presidential address.
Sartorelli, A. C. (1988) · PubMed · Cited by 278
Overgaard, J., Sand Hansen, H., Jøsrgensen, K., & Hjelm Hansen, M. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90058-1 · Cited by 239
Cited by
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Self-citationDrug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Chemodynamic Therapy: Tumour Microenvironment‐Mediated Fenton and Fenton‐like Reactions
Tang, Z., Liu, Y., He, M., & Bu, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201805664 · Cited by 1,951
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Overcoming the Achilles' heel of photodynamic therapy
Fan, W., Huang, P., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00616g · Cited by 1,684
The comet assay: a comprehensive review
Fairbairn, D. W., Olive, P. L., & O'Neill, K. L. (1995) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/0165-1110(94)00013-3 · Cited by 1,664
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894
Nunes, A. S., Barros, A. S., Costa, E. C., Moreira, A. F., & Correia, I. J. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26845 · Cited by 721
Hypoxia and hypoxia-inducible factors: master regulators of metastasis
Lu, X., & Kang, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1360 · Cited by 723
Tatum, J. L. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000601002324 · Cited by 620
Mitomycin C: small, fast and deadly (but very selective)
Tomasz, M. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90120-5 · Cited by 581
Teicher, B. A. (1994) · Cancer and Metastasis Reviews · doi:10.1007/bf00689633 · Cited by 563
Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies
Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., & Toomey, D. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00003-3 · Cited by 559
Enzyme-Catalyzed Activation of Anticancer Prodrugs
Rooseboom, M., Commandeur, J. N. M., & Vermeulen, N. P. E. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.1.3 · Cited by 497
The concurrent chemoradiation paradigm—general principles
Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0714 · Cited by 443
Emerging Strategies of Nanomaterial‐Mediated Tumor Radiosensitization
Xie, J., Gong, L., Zhu, S., Yong, Y., Gu, Z., & Zhao, Y. (2019) · Advanced Materials · doi:10.1002/adma.201802244 · Cited by 415
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies
Brown, J. M. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01677-4 · Cited by 350
Self-citationAirley, R. E., & Mobasheri, A. (2007) · Chemotherapy · doi:10.1159/000104457 · Cited by 342
Wang, M., Chang, M., Chen, Q., Wang, D., Li, C., Hou, Z., Lin, J., Jin, D., & Xing, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120093 · Cited by 322
Recent Advances in Glucose‐Oxidase‐Based Nanocomposites for Tumor Therapy
Wang, M., Wang, D., Chen, Q., Li, C., Li, Z., & Lin, J. (2019) · Small · doi:10.1002/smll.201903895 · Cited by 302
von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P., Talbot, D., Rey, A., Butler, T. W., Hirsh, V., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1351 · Cited by 285
Tomasz, M., & Palom, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00088-0 · Cited by 283
Development of a hypoxia-responsive vector for tumor-specific gene therapy
Shibata, T., Giaccia, A. J., & Brown, J. M. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301124 · Cited by 266
Self-citationToustrup, K., Sørensen, B. S., Nordsmark, M., Busk, M., Wiuf, C., Alsner, J., & Overgaard, J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1182 · Cited by 255
On The Latest Three‐Stage Development of Nanomedicines based on Upconversion Nanoparticles
Fan, W., Bu, W., & Shi, J. (2016) · Advanced Materials · doi:10.1002/adma.201505678 · Cited by 252
Chemodynamic Therapy: Tumour Microenvironment‐Mediated Fenton and Fenton‐like Reactions
Tang, Z., Liu, Y., He, M., & Bu, W. (2019) · Angewandte Chemie · doi:10.1002/ange.201805664 · Cited by 240
Targeting hypoxia cell signaling for cancer therapy
Melillo, G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9059-x · Cited by 230
Covalent Modification of DNA by Natural Products
Gates, K. S. (1999) · Comprehensive Natural Products Chemistry · doi:10.1016/b978-0-08-091283-7.00074-6 · Cited by 44
Metadata
- Authors
- Brown, J.
- Venue
- British Journal of Cancer
- Published
- 1993-06
- Volume
- 67
- Issue
- 6
- Pages
- 1163-1170
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2145953677
- Cited by
- 366
- References
- 44
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.